Proceeds from non-marketable securities
Merck & Co. Proceeds from non-marketable securities decreased by 92.0% to $46.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 557.1%, from $7.00M to $46.00M. Over 4 years (FY 2021 to FY 2025), Proceeds from non-marketable securities shows an upward trend with a 13.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Higher proceeds suggest successful exits from strategic investments or a shift toward liquidating non-core assets to generate cash.
Detailed definition
This metric tracks cash inflows resulting from the sale, redemption, or maturity of investments that do not have a readi...
Peer comparison
Often found in the investing section of cash flow statements for companies with significant corporate venture capital or strategic investment arms.
cf_aapl_proceeds_from_non_marketable_securitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $256.50M | $256.50M | $256.50M | $180.25M | $180.25M | $180.25M | $180.25M | $500.00M | $285.00M | $704.00M | $169.00M | $260.00M | $60.00M | $50.00M | $7.00M | $456.00M | $601.00M | $575.00M | $46.00M |
| QoQ Change | — | +0.0% | +0.0% | -29.7% | +0.0% | +0.0% | +0.0% | +177.4% | -43.0% | +147.0% | -76.0% | +53.8% | -76.9% | -16.7% | -86.0% | >999% | +31.8% | -4.3% | -92.0% |
| YoY Change | — | — | — | — | -29.7% | -29.7% | -29.7% | +177.4% | +58.1% | +290.6% | -6.2% | -48.0% | -78.9% | -92.9% | -95.9% | +75.4% | +901.7% | >999% | +557.1% |
Proceeds from non-marketable securities at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s proceeds from non-marketable securities?
- Merck & Co. (MRK) reported proceeds from non-marketable securities of $46.00M in Q4 2025.
- How has Merck & Co.'s proceeds from non-marketable securities changed year-over-year?
- Merck & Co.'s proceeds from non-marketable securities increased by 557.1% year-over-year, from $7.00M to $46.00M.
- What is the long-term trend for Merck & Co.'s proceeds from non-marketable securities?
- Over 4 years (2021 to 2025), Merck & Co.'s proceeds from non-marketable securities has grown at a 13.1% compound annual growth rate (CAGR), from $1.03B to $1.68B.
- What does proceeds from non-marketable securities mean?
- Cash received from selling or redeeming private or non-traded investments.